# A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

> **NCT01006122** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 95 (actual)

## Conditions studied

- Excessive Daytime Sleepiness
- Narcolepsy

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-03654746

## Key facts

- **NCT ID:** NCT01006122
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006122, "A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01006122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*